Nuvation Bio Inc. (NUVB) has a consensus analyst rating of Buy, based on 9 analysts covering the stock. Of those, 7 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for NUVB is $12.40, representing a +155.7% upside from the current price of $4.85. Price targets range from a low of $10.00 to a high of $17.00.
